Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 4/20 | 0.38 |
| ▸ | RORC | P51449 | 4/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.35 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CDC7 | O00311 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4247336 | 0.94 | L3MBTL1 (0.42) | ROCK1RORCCYP2C9CYP3A4HTR3A | |
| SCHEMBL4245432 | 0.89 | RORC (0.36) | ROCK1RORCCYP2C9CYP3A4HTR3A | |
| SCHEMBL4240873 | 0.88 | PIK3R2 (0.47) | RORCCYP2C9CYP3A4HTR3APIK3R2 | |
| SCHEMBL4240984 | 0.87 | NCF1 (0.43) | RORCCYP2C9CYP3A4HTR3AL3MBTL1 | |
| Hydrochloric Acid SCHEMBL4239416 | 0.86 | NCF1 (0.43) | RORCCYP2C9CYP3A4HTR3AL3MBTL1 | |
| SCHEMBL4247339 | 0.85 | MALT1 (0.35) | ROCK1RORCCYP2C9CYP3A4HTR3A | |
| SCHEMBL4247704 | 0.84 | HTR3A (0.38) | ROCK1HTR3AMALT1 | |
| SCHEMBL4243769 | 0.83 | CD38 (0.40) | RORCCYP2C9CYP3A4ADORA2AADORA1 | |
| Hydrochloric Acid SCHEMBL4236769 | 0.83 | HTR3A (0.38) | ROCK1HTR3ANPC1RAB9AMALT1 | |
| SCHEMBL4240870 | 0.82 | ROCK1 (0.37) | ROCK1RORCCYP2C9CYP3A4HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040214820-A1 | 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-28 | — | — | US | claimed |
| US-7638521-B2 | 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-12-29 | — | — | US | disclosed |
| US-20040214820-A1 | 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214820-A1 | 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them | IDO1, IDO2, HTR3C | ROCK1 966/4885RORC 464/4885CYP2C9 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.